- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01775319
Evaluation of Human Zinc Absorption From Wheat-based Meals
Study part 1 and 2 Assessment of Zn absorption from regular and biofortified wheat: stable isotope absorption studies in women of childbearing age consuming test meals prepared from either the biofortified Zn wheat, regular wheat or post-harvest fortified wheat at two different extraction rates.
Study part 3 Assessment of Zn absorption from intrinsically and extrinsically labeled wheat: stable isotope absorption studies in women of childbearing age, or men, consuming test meals prepared from either intrinsically labeled Zn biofortified wheat, regular wheat or post-harvest fortified wheat extrinsically labeled immediately before consumption.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall goal of study part 1 and 2 is to evaluate and compare the fractional and absolute Zn absorption from biofortified wheat cultivar (60 ppm Zn) to regular wheat (28 ppm Zn) and to post harvest fortified wheat (60 ppm Zn) for a total of 3 test meals per study. The studies will be conducted with products based on wheat with high extraction rate (study part 1) and medium extraction rate (study part 2) in two separate groups of women of childbearing age.
The goal of study part 3 is to investigate the difference of absorption measurements between intrinsically and extrinsically labeled biofortified wheat. The label of the test meals will have the same nature as the fortificant itself (extrinsic vs intrinsic), for a total of 3 test meals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female, 18 to 45 years old (Study part 1 and 2). Female or male, 18 to 45 years old (Study part 3)
- Body Mass Index in the range of 18.5 to 25 kg/m2
- Signed informed consent
Exclusion Criteria:
- Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, anemia, hepatitis, hypertension, cancer or cardiovascular diseases (according to the subjects own statement)
- Gluten intolerance, celiac disease
- Continuous/long-term use of medication during the whole study (except for contraceptives)
- Vegans
- Consumption of mineral and vitamin supplements within 2 weeks prior to 1st test meal administration
- Smoking
- Pregnancy (Urine pregnancy test shall be performed before each test meal administration)
- Lactating
- Earlier participation in a study using Zn stable isotopes or participation in any other clinical study within the last 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Biofortified wheat
|
Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
Other Names:
|
Placebo Comparator: Control wheat
Control wheat with low level of Zn
|
|
Active Comparator: Fortified wheat
Wheat fortified before consumption
|
Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fractional zinc absorption from different wheat-based test meals
Time Frame: 3 months
|
Fractional zinc absorption (in %) will be assessed with stable isotopes of zinc using a double isotope technique.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Zn and C-reactive protein concentration in plasma
Time Frame: 3 months
|
3 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Creatinin
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Diego Moretti, PhD, Swiss Federal Institute of Technology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HNL/CTC_Zn_wheat
- KEK-ZH-2012-0483 (Other Identifier: KEK-Zurich)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Zinc Deficiency
-
NobelpharmaCompleted
-
Swiss Federal Institute of TechnologyHarvestPlusCompleted
-
Prof. Michael B. ZimmermannUniversité d'Abomey-CalaviCompleted
-
University of California, DavisHelen Keller International; Cheikh Anta Diop University, Senegal; Global Alliance...Completed
-
NobelpharmaCompleted
-
International Centre for Diarrhoeal Disease Research...University of California, DavisCompleted
-
University of California, DavisHelen Keller International; Université Polytechnique de Bobo-Dioulasso; NutrisetCompletedZinc DeficiencyBurkina Faso
-
Wageningen UniversityETH Zurich; Maseno UniversityCompletedZinc DeficiencyKenya
-
University of California, DavisUSDA, Western Human Nutrition Research CenterCompleted
-
University of California, DavisHelen Keller International; Cheikh Anta Diop University, Senegal; Global Alliance...Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States